Versanis Bio
Part of Eli Lilly and Company
Company
Versanis Bio develops one asset, in phase 3 (bimagrumab in sporadic inclusion body myositis). Mostly antibody acting on ACVR2B.
- 1
- Asset
- Furthest stage
- Phase 3
- 0
- Trials
- 5
- Signals
Pipeline
1Blocks activin type II receptors, promoting muscle growth and reducing fat mass.
Phase 3, Antibody, ACVR2B, sporadic inclusion body myositis, sarcopenia (Phase 2), Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Signals20
- Similar companies6